Omeros (OMER) to Offer $40M in Common Stock
- Stocks decline as interest rate uncertainty, earnings weigh
- ASML slides as Q1 sales fall short but firm still on track for 2025 revenue target
- US dollar weakens as market consolidates gains, but uptrend intact
- Abbott Laboratories (ABT) narrows 2024 earnings guidance, shares slip
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- GE HealthCare (GEHC) Announces Resignation of Jan Makela, CEO of Imaging
- Barnes & Noble Education (BNED) Enters Definitive Agreement with Immersion (IMMR)
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
Omeros Announces Public Offering of Common Stock
August 10, 2016 4:01 PM EDTSEATTLE, Aug. 10, 2016 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced an agreement to sell $40 million of shares of its common stock to Cantor Fitzgerald & Co., as the sole underwriter, in a registered underwritten public offering.
Omeros intends to use the net proceeds of the offering for general corporate purposes, including funding research and development expenses for its clinical OMS721 program and clinical trials, pre-clinical studies, manufacturing development and other costs associated with advancing its product candidates toward Biologic License Application and New Drug Application submissions, and supporting the continued... More